资源描述:
《中晚期卵巢癌术后化疗临床观察》由会员上传分享,免费在线阅读,更多相关内容在工程资料-天天文库。
1、中晚期卵巢癌术后化疗临床观察【摘要】目的分析两种给药途径(顺钳+紫杉醇静脉化疗,顺钳+紫杉醇腹腔化疗)对中晚期卵巢癌术后的化疗效果。方法选择2011年6月至2012年6月本院收治的确诊为卵巢癌中晚期并已行肿瘤细胞减灭术后的48例患者,随机分为腹腔化疗组,静脉化疗组,各24例,观察两组不良反应,近期疗效,化疗完成情况等。结果腹腔化疗组和静脉化疗组的有效率分别为83.3%(20/24)和79.1%(19/24),差异无统计学意义(P>0.05),毒副反应的发生率腹腔化疗组为95.8%(23/24),静脉化疗组100%(24/24),差异无统计学
2、意义(P>0.05)o但重度消化道副作用腹腔化疗组33.3%(8/24),静脉化疗组0%(0/24),差异有统计学意义(P0.05),见表2。2.2毒副反应腹腔化疗组及静脉化疗组患者毒副反应主要为骨髓抑制,表现为白细胞明显下降,对血小板及血红蛋白影响较小。注射局部静脉炎,脱发,消化道反应及周围神经毒性两组发生率近似(见表3),均未出现心肝、肾功能损害、肠梗阻及发热,过敏反应,但静脉给药组中重度消化道反应(II度及III度)8例(33.3%),腹腔化疗组2例(8.3%),两组间比较差异有统计学意义(P[7]BamiasA,BamiaC,Zag
3、ouriF,etal.Improvedsurvivaltrendsinpla.tinum-resistantpatientswithadvancedovarian,fallopianorperitonealcancertreatedwithfirst-linepaditaxel/platinumchemotherapy:theimpactofnovelagents.Oncology,2013,84(3):158-65._8]LeeSE,BairstowSF,WerlingJO,etal.Paclitaxelnanosuspensionsfo
4、rtargetedchemotherapy-nanosuspensionpreparation,characterization,anduse・PharmDevTechnol,2013Apr25.[9]曹泽毅•妇科常见肿瘤诊治指南.3版.北京:人民卫生出版社,2010:7293.[10]JordanS,SteerC,DefazioA,etaLPatternsofchemotherapytreatmentforwomenwithinvasiveepithelialovariancancer-Apopulation—basedstudy.Gyn
5、ecolOncol,2013,129(2):310-7..11]LandrumLM,JavaJ,MathewsCA,etal.PrognosticfactorsforstageIIIepithelialovariancancertreatedwithintraperitonealchemotherapy:AGynecologicOncologyGroupstudy.GynecolOncol,2013:S0090-8258(13)00214-X.」2]MendivilAA,MichaJP,BrownJV,etal.Increasedincid
6、enceofseveregastrointestinaleventswithfirst-linepaditaxel,carboplatin,andvorinostatchemotherapyforadvanced-stageepithelialovarian,primaryperitoneal,andfallopiantubecancer.IntJGynecolCancer,2013,23(3):533-9・[13]ChangCL,HsuYT,WuCC,etal.Dose-densechemotherapyimprovesmechanism
7、sofantitumorimmuneresponse・CancerRes,2013,73(1):119-27・[14]NCCNclinicalpracticeGuidelinesinOncology:OvarianCancer.V.2.2011,0V-3[EB/OL].http://www.nccn.org,2011-10-20..15]GlazeS,TeitelbaumL,ChuP,etal.Dose-densePaditaxelwithCarboplatinforadvancedovariancancer:afeasibletreatm
8、entalternative.JObstetGynaecolCan,2013,35(1):61-7.